CELLIVERY
ABOUT US
HISTORY
STORY OF
CELLIVERY
Cellivery Therapeutics Inc. was founded by Dr. Daewoong Jo, President and CEO in March of 2014. Its earliest notions have been prepared, however, when Dr. Jo began to study for his doctoral thesis at Vanderbilt University, Nashville, TN, USA in 1997.
Dr. Daewoong Jo is a long-time expert of the cutting-edge technology-based biotech industry who has experienced more than 18 years as scientist, professor and businessman in US and Korea. He contributed to multiple numbers of protein-based new drug discovery by using TSDT platform he mastered for innovative new drug development. His extensive knowledge and experience in TSDT platform, its application to various fields of biomedical sciences and businesses make him and his colleagues excellent resource for the Company as we prepare to advance our mission into pivotal drug development.
-
2019
Completion of USA CP-△SOCS3 Obesity Therapy Patent Registration US(10323072)
Completion of Korea aMTD/TSDT Platform Patent Registration KR(101971021)
Completion of USA aMTD/TSDT Platform Patent Registration US(10323063)
Completion of Japan aMTD/TSDT Platform Patent Registration JP(6559227)
Completion of USA iCP-SOCS3 Hepatocellular Carcinoma Therapy Patent Registration US(10385103)
Completion of Australia iCP-Parkin Parkinson's Disease Therapy Patent Registration AU(2016299468)
Completion of USA iCP-RFs iPSC Reprogramming Factors Patent Registration US(15/884651)
Completion of USA CP-BMP2 Bone Healing Therapy Patent Registration US(15/884884)
Completion of EU iCP-Parkin Parkinson's Disease Therapy Patent Registration EP(16830820.3)
Completion of EU iCP-RFs iPSC Reprogramming Factors Patent Registration EP(16835416.5)
-
2018
Completion of Australia aMTD/TSDT Platform Patent Registration AU(2015304194)
Cellivery Therapeutics, to be listed on KOSDAQ
「Research Collaboration」 with one of the Top 10 Global Big Pharma
「Feasibility Study」 with one of the Top 40 Global Big Pharma
「Research Collaboration」 with one of the Top 20 Global Big Pharma
Grant Support from Small and Medium Business Administration (Grant ID: S2579740)
Grant Support from Ministry of Health & Welfare (Grant ID: H18C1986)
Grant Support from Korea Intellectual Property Strategy Agency (Grant ID: 18IC41C019)
Began Preclinical/Clinical Trials of Anti-Pancreatic Cancer Agent
CDA/MTA/FSA Executed with one of the Top 20 Global Big Pharma
CDA/MTA/FSA Executed with one of the Top 40 Global Big Pharma
11’th Equity Investment
-
2017
Grant Support from Michael J. Fox Foundation Core Funding Programs (Grant ID: MJFF14241)
Grant Support from Small and Medium Business Administration (Global Star Venture R&D Project, Project ID: S2516999)
Grant Support from Small and Medium Business Administration (Cooperation Equipment Application Plan, Project ID: C0486076)
Began Preclinical/Clinical Trials of Anti-Parkinson's Disease Agent
CDA/MTA/FSA Executed with one of the Top 20 Global Big Pharma
CDA/MTA/FSA Executed with one of the Major Global Distributor
10th Equity Investment
-
2016
Commercialization of Research Reagents (iCP-Cre&iCP-RFs)
Grant Support from Small and Medium Business Administration
Grant Support from Ministry of Trade, Industry and Energy
9th Equity Investment
Collaboration Agreement with Ildong Pharmaceuticals Co., Ltd.
Agreement on Collaboration for Research Reagent Commercialization with Daejung Chemicals & Metals Co., Ltd.
-
2015
6~8th Equity Investment
Research & Business Partnering with Vanderbilt University
Dr. Earl Ruley Joined as Company's Science & Business Advisor
Grant Support from Small and Medium Business Administration
13 Patent Applications: TSDT Platform & Protein-Based Biotherapeutics (Anti-Cancer Agent, Anti-Neurodegenerative Disease Agent, Pro-Osteogenetic Agent, Anti-Obesity Agent) and Research Reagents (iCP-Cre&iCP-RFs)
-
2014
4~5th Equity Investment
Headquater Relocated in Seoul
4 Patent Application in TSDT & 3 Drug Candidates
R&D Fund Support from Ministry of Science, ICT and Future Planning
1st ~ 3rd Equity Investment
Cellivery Therapeutics, Inc. Founded in Busan, Korea
Published Papers about Stem Cell Therapy and Parkinson's Disease in Scientific Reprots and PLoS ONE
-
2013
Published papers about Cancer Therapy in Clinical Cancer Research and Biomaterials
-
2012
Published a paper about Cancer Therapy in Molecular Therapy
-
2011
Published about Protein Replacement Therapy in Cancer Research
Dr. Jo took sabbatical leave at Vanderbilt Univ& collaborated with El-Rifai group
-
2006
Dr. Jo came back to Korea to take professorship at Chonnam National University Medical School
The first TSDT-based bioventure company founded by Dr. Jo